Efficacy and Safety of Nipocalimab in Primary Sjogren's Disease: Results From a Phase 2, Randomized, Double-blind DAHLIAS Study

Jacques Eric Gottenberg,¹ Kathy Sivils,² Kim Campbell,² Jada Idokogi,² Kim Lo,² Sophia G. Liva,² Jonathan Shelton,³ Harman Dhatt,⁴ Jonathan J. Hubbard,² Ghaith Noaiseh⁵ ¹Department of Rheumatology, Strasbourg University, Institute of Molecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rheumatology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, France; ²Janssen Research & Development, LLC, Spring House, PA, USA; ¹Department of Rolecular and Cellular Biology, Strasbourg, Strasbour ³Janssen Scientific Affairs, LLC, San Diego, CA, USA; ⁴Janssen Global Services, LLC, Raritan, NJ, USA; ⁵Division of Allergy, Clinical Immunology and Rheumatology, Department of Medicine, University of Kansas, Kansas City, KS, USA

Background

- Sjögren's disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of autoantibodies, lymphocytic infiltration of exocrine glandular tissues, and systemic organ and tissue injury¹
- Dysregulated humoral immunity involving aberrant B-lymphocyte activity leading to abnormally elevated levels of immunoglobulin (Ig) G and IgG autoantibodies, particularly anti-Ro and anti-La autoantibodies, has been implicated in SiD¹
- SjD is associated with substantial disease burden, with symptoms that include mucosal dryness, fatigue, and pain,^{2,3} and ~1.5-fold higher all-cause mortality⁴
- Neonatal crystallizable fragment receptor (FcRn) is a transmembrane protein that is involved with IgG recycling and transcytosis as well as innate and adaptive immune function⁵
- Nipocalimab is a fully human IgG1 monoclonal antibody that binds with high affinity to the IgG binding site of the FcRn
- As an FcRn blocker, nipocalimab decreases levels of IgG and IgG autoantibodies without broad immunosuppression
- The efficacy of nipocalimab has been established in generalized myasthenia gravis and hemolytic disease of the fetus and newborn^{6,}

Objective

• To evaluate the efficacy and safety of nipocalimab in patients with SjD

Results


- In total, 163 participants were enrolled (**Table 1**)
- Demographic and baseline disease characteristics were comparable among groups

TABLE 1: Demographic and baseline disease characteristics

		Nipocalimab		
Characteristic	Placebo (n=56)	5 mg/kg Q2W (n=53)	15 mg/kg Q2W (n=54)	All participants (N=163)
Age, years, median (range)	46.5 (23–73)	49.0 (20–72)	48.5 (24–72)	48.0 (20–73)
Female, %	92.9	92.5	92.6	92.6
White, %	89.3	92.5	90.7	90.8
Time since diagnosis, years, median (range)	4.0 (0.6–34.0)	3.7 (0.6–27.9)	4.3 (0.6–18.2)	4.0 (0.6–34.0)
ClinESSDAI score, mean (SD)	10.0 (3.8)	9.4 (3.1)	10.2 (3.6)	9.9 (3.5)
ESSPRI score, mean (SD)	7.0 (1.3)	7.0 (1.3)	7.2 (1.2)	7.1 (1.2)
Total IgG levels,ª g/L, median (range)	14.8 (7.7–40.5)	14.8 (4.6–35.2)	15.5 (7.6–49.6)	14.9 (4.6–49.6)
Autoantibody positivity, n	55	52	53	160
Anti-Ro60, %	98.2	98.1	98.1	98.1
Anti-La, %	74.5	76.9	64.2	71.9
Anti-Ro52, %	78.2	86.5	77.4	80.6
RF, %	78.6	71.7	63.0	71.2

(least squares mean difference, –2.65; 90% CI, –4.03, –1.28; *P*=0.002; Figure 2)


FIGURE 2: Change from baseline in ClinESSDAI score



^aMeasured at a central laboratory. Reference range was 6.03 to 16.13 g/L. ClinESSDAI=Clinical European League Against Rheumatisn Sjögren's Syndrome Disease Activity Index; ESSPRI=European League Against Rheumatism Sjögren's Syndrome Patient Reported Index; IgG=Immunoglobulin G; Q2W=Every 2 weeks; RF=Rheumatoid factor; SD=Standard deviation.

GN: advisory board member of Janssen and Novartis. Previously presented at APLAR 2024; Suntec, Singapore; August 21-25, 2024.

CI=Confidence interval; ClinESSDAI=Clinical European Leaaue Aaainst Rheumatism Siöaren's Svndrome Disease Activity Index: LS=Lea squares; NS=Nonsignificant; Q2W=Every 2 weeks; SE=Standard error.



• The nipocalimab 15 mg/kg group met the primary endpoint versus placebo

Similar improvements in the nipocalimab 15 mg/kg group versus placebo were observed in most secondary and supportive endpoints (Tables 2 and 3)

TABLE 2: Change from baseline at Week 24 in selected secondary and supportive endpoints

	LS mean differ nipocalimab	Nominal <i>P</i> value:	
Endpoint	5 mg/kg Q2W (n=53)	15 mg/kg Q2W (n=54)	nipocalimab 15 mg/kg Q2W vs placebo
PhGA	-2.26 (-8.50, 3.99)	–14.50 (–20.81, –8.19)	<0.001
ESSDAI	–0.52 (–1.67, 0.63)	–1.79 (–2.94, –0.63)	0.012
ESSPRI	0.62 (0.01, 1.23)	-0.41 (-1.03, 0.20)	0.268

neasures model with baseline score, study treatment, visit, reaion.

TABLE 3: Responder rate at Week 24 for selected secondary and supportive endpoints

articipants with an intercurrent event per protocol were considered to have missing data thereafter. (

aseline steroid use, baseline antimalarial use, and an interaction of treatment and visit as terms in the model. For continuous endpoint

Syndrome Patient Reported Index; LS=Least squares; PhGA=Physician Global Assessment of Disease Activity; Q2W=Every 2 weeks.


uropean Leaaue Aaainst Rheumatism Siöaren's Svndrome Disease Activity Index: ESSPRI=European League Against Rheumatism Sjögren

supportive endpoints					
	Difference in propo nipocalimab	Nominal <i>P</i> value:			
Endpoint	5 mg/kg Q2W (n=53)	15 mg/kg Q2W (n=54)	nipocalimab 15 mg/kg Q2W vs placebo		
ESSDAI-3	9.5 (–5.8, 24.8)	16.1 (0.8, 31.4)	0.172		
STAR	11.7 (–3.9, 27.2)	23.7 (8.4, 38.9)	0.017		
CRESS	25.5 (11.5, 39.5)	30.3 (16.3, 44.3)	0.001		
DAL ^b	18.9 (3.6, 34.2)	19.8 (4.5, 35.0)	0.046		

Values are percentages. Statistical comparisons with the placebo group used a Cochran-Mantel-Haenszel test with region, baseline steroid use, and baseline antimalarial use as stratification factors. For binary composite endpoints, participants with intercurrent events were considered nonresponders after the event. ^bDAL response is a reduction from baseline in DAL by ≥ 1 level in ≥ 1 ClinESSDAI domain (eg, articular, hematological, cutaneous, constitutional). CI=Confidence interval; ClinESSDAI=Clinical European League Against Rheumatism Siöaren's Syndrome Disease Activity Index: CRESS=Composite of Relevant Endpoints for Sjögren's Syndrome; DAL=Disease activity level; $\vec{ESSDAI-3} = Improvement of \geq 3 points from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index score;$ Q2W=Every 2 weeks; STAR=Sjögren's Tool for Assessing Response.




 Nipocalimab 15 mg/kg treatment resulted in greater reductions from baseline in ESSPRI score from Weeks 12 through 24 compared to placebo (Figure 3




• The proportion of participants with $\geq 50\%$ improvement from baseline in UWS at Week 24 in the nipocalimab 15 mg/kg group was more than double that of the placebo group (**Figure 4**)





- Significant nipocalimab dose-dependent reductions from baseline in total IgG antibody and IgG autoantibody levels were observed (**Figure 5**)
- There was a **77% maximum reduction** in total IgG, as determined by pharmacokinetic/pharmacodynamic simulations
- There was a median predose (minimum) observed reduction of 61% in total IgG at Week 24
- Consistent reductions in SiD-associated anti-Ro60. anti-Ro52. and anti-La IgG autoantibodies were observed

FIGURE 5: Median (IQR) minimum observed percent change from baseline in IgG antibody levels over time



Q2W=everv 2 weeks.

Key Takeaway

In adults with active Sjögren's disease, treatment with nipocalimab 15 mg/kg for 24 weeks led to reduced IgG autoantibody levels and improved clinical and patient-reported outcomes compared to placebo

Conclusions



- The DAHLIAS study established proof of concept for nipocalimab in Sjögren's disease
 - Nipocalimab 15 mg/kg led to significant improvement versus placebo in ClinESSDAI score and demonstrated similar trends in other key efficacy endpoints
 - Nipocalimab treatment was well tolerated, with no new safety signals observed

These findings established the clinical benefits of reducing IgG autoantibody levels for the treatment of Sjögren's disease

These findings support further clinical evaluation of nipocalimab, a novel FcRn blocker, in Sjögren's disease and other autoantibody-associated rheumatic diseases

- Serious adverse events (AEs) were reported in 7.5%, 7.4%, and 5.4% of participants in the nipocalimab 5 mg/kg, nipocalimab 15 mg/kg, and placebo groups, respectively (**Table 4**)
- One participant in the nipocalimab 5 mg/kg group experienced a serious AE reported by the preferred term "anaphylactic reaction," which presented as tachycardia, hypertension, dyspnea, and urticaria during the 10th administration of study treatment
- Severe infections or infections requiring IV anti-infectives occurred in 3.8%, 1.9%, and 1.8% of participants in the nipocalimab 5 mg/kg, nipocalimab 15 mg/kg, and placebo groups, respectively, without a clear correlation with IgG nadir; none were deemed related to study treatment

TABLE 4: AEs and serious AEs

		Nipocalimab		
Participants with ≥1 AE, n (%)	Placebo (n=56)	5 mg/kg Q2W (n=53)	15 mg/kg Q2W (n=54)	Combined (n=107)
AEs	35 (62.5)	42 (79.2)	43 (79.6)	85 (79.4)
Serious AEs	3 (5.4)	4 (7.5)	4 (7.4)	8 (7.5)
Infections and infestations	24 (42.9)	32 (60.4)	28 (51.9)	60 (56.1)
Severe infections ^a	1 (1.8)	2 (3.8)	1 (1.9)	3 (2.8)
Opportunistic infections	0	0	0	0
Infusion reactions	2 (3.6)	6 (11.3)	1 (1.9)	7 (6.5)
Hypersensitivity reactions	3 (5.4)	6 (11.3)	7 (13.0)	13 (12.1)
MACE ^b	2 (3.6)	0	0	0

^aInfections that were severe or required IV anti-infective or operative/invasive intervention, as assessed by the investigator. ^bCardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. AE=Adverse event; IV=Intravenous; MACE=Major adverse cardiovascular events; Q2W=Everv 2 weeks.

- In the nipocalimab 15 mg/kg group, mean changes from baseline at Week 24 in albumin (–6.9%), low-density lipoprotein cholesterol (6.6%), and total cholesterol (8.3%) were not clinically significant
- Severe hypoalbuminemia (<20 g/L) was not observed; no deaths were reporte
- The safety profile of nipocalimab was consistent with findings from patients with myasthenia gravis, rheumatoid arthritis, and hemolytic disease of the fetus and newborn^{6,7}